Consequently, we hypothesize that the development of METTL14-targeted inhibitors could have a substantial impact on the clinical management of renal cell carcinoma, paving the way for new therapeutic approaches. The gene discussed is METTL14; the disease is hereditary clear cell renal cell carcinoma.